IQVIA
About: IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Employees: 88,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 15 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
45% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 77
23% more repeat investments, than reductions
Existing positions increased: 429 | Existing positions reduced: 350
8% more funds holding in top 10
Funds holding in top 10: 12 [Q2] → 13 (+1) [Q3]
7% more capital invested
Capital invested by funds: $34.2B [Q2] → $36.7B (+$2.43B) [Q3]
3% more funds holding
Funds holding: 1,002 [Q2] → 1,037 (+35) [Q3]
3.73% less ownership
Funds ownership: 88.92% [Q2] → 85.19% (-3.73%) [Q3]
11% less call options, than puts
Call options by funds: $208M | Put options by funds: $234M
Research analyst outlook
15 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$212
6%
upside
Avg. target
$254
27%
upside
High target
$276
38%
upside
15 analyst ratings
14 positive
93%
1 neutral
7%
0 negative
0%
Stephens & Co. Jeff Garro 50% 1-year accuracy 4 / 8 met price target | 25%upside $250 | Overweight Initiated | 20 Dec 2024 |
B of A Securities Derik De Bruin 26% 1-year accuracy 5 / 19 met price target | 17%upside $235 | Buy Maintained | 13 Dec 2024 |
Truist Securities Jailendra Singh 23% 1-year accuracy 8 / 35 met price target | 30%upside $261 | Buy Maintained | 12 Dec 2024 |
RBC Capital Sean Dodge 50% 1-year accuracy 21 / 42 met price target | 35%upside $270 | Outperform Reiterated | 11 Dec 2024 |
Baird Eric Coldwell 32% 1-year accuracy 11 / 34 met price target | 6%upside $212 | Neutral Maintained | 11 Dec 2024 |
Financial journalist opinion
Based on 4 articles about IQV published over the past 30 days
Positive
Zacks Investment Research
3 days ago
IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains?
IQVIA (IQV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Business Wire
3 days ago
Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in scope and function to aid patient diagnosis, treatment, and monitoring. More solutions are now focused on specific diseases, and their commercial appeal has grown as developers build solutions that bring value back to providers, are more easily integrated with health systems, and embrace innovatio.
Neutral
Seeking Alpha
2 weeks ago
IQVIA Holdings: Share Price Disconnected From Growth Outlook
IQVIA continues to outperform earnings expectations, despite a 14% stock decline, driven by concerns of a CRO industry slowdown and reduced early-stage R&D spending. Q3 results show strong performance with $3.9B revenue, 14.1% EPS growth, and a $31.1B backlog, reinforcing long-term growth potential. Analysts project slower CRO growth, but IQVIA's leadership, consistent earnings, and long-term revenue estimates of $28.45B by 2033 support a bullish outlook.
Positive
Zacks Investment Research
4 weeks ago
Why You Should Retain IQVIA Holdings Stock in Your Portfolio Now
IQV is known for its innovative use of technology and data analytics.
Neutral
Business Wire
1 month ago
IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA.
Positive
Zacks Investment Research
1 month ago
Interpreting IQVIA (IQV) International Revenue Trends
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Neutral
Zacks Investment Research
1 month ago
IQVIA (IQV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neutral
Seeking Alpha
1 month ago
IQVIA Holdings Inc. (IQV) Q3 2024 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV ) Q3 2024 Results Conference Call October 31, 2024 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations & Treasury Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Eric Sherbet - Executive Vice President and General Counsel Mike Fedock - Senior Vice President, Financial Planning and Analysis Gustavo Peroni - Senior Director, Investor Relations Conference Call Participants Ann Hynes - Mizuho Shlomo Rosenbaum - Stifel Anne Samuel - JP Morgan Luke Sergott - Barclays Bank Justin Bowers - Deutsche Bank David Windley - Jefferies Elizabeth Anderson - Evercore ISI Michael Cherny – Leerink Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Third Quarter 2024 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
IQVIA Earnings & Revenues Surpass Estimates in Q3, Increase Y/Y
Strength in the Research and Development, and Technology and Analytics segments drives IQV's top line in the third quarter of 2024.
Negative
Reuters
1 month ago
IQVIA lowers annual revenue forecast amid trial delays
Contract research firm IQVIA lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges.
Charts implemented using Lightweight Charts™